RENX Stock Overview
Develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Renalytix Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.077 |
| 52 Week High | UK£0.75 |
| 52 Week Low | UK£0.07 |
| Beta | 2.07 |
| 11 Month Change | 3.33% |
| 3 Month Change | -27.91% |
| 1 Year Change | -65.56% |
| 33 Year Change | -98.88% |
| 5 Year Change | -97.19% |
| Change since IPO | -93.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| RENX | GB Healthcare Services | GB Market | |
|---|---|---|---|
| 7D | -3.1% | -2.0% | -0.3% |
| 1Y | -65.6% | 25.2% | 6.1% |
Return vs Industry: RENX underperformed the UK Healthcare Services industry which returned 25.2% over the past year.
Return vs Market: RENX underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| RENX volatility | |
|---|---|
| RENX Average Weekly Movement | 8.3% |
| Healthcare Services Industry Average Movement | 6.2% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: RENX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: RENX's weekly volatility has decreased from 36% to 8% over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | James McCullough | renalytix.com |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management kidney diseases in the United States. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Renalytix Plc Fundamentals Summary
| RENX fundamental statistics | |
|---|---|
| Market cap | UK£25.67m |
| Earnings (TTM) | -UK£26.39m |
| Revenue (TTM) | UK£1.81m |
14.2x
P/S Ratio-1.0x
P/E RatioIs RENX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RENX income statement (TTM) | |
|---|---|
| Revenue | US$2.29m |
| Cost of Revenue | US$2.13m |
| Gross Profit | US$156.00k |
| Other Expenses | US$33.61m |
| Earnings | -US$33.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 6.82% |
| Net Profit Margin | -1,461.60% |
| Debt/Equity Ratio | -108.1% |
How did RENX perform over the long term?
See historical performance and comparison